A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 40-45

  Saraswat, Abir ^a,d   Agarwal, Ravindra ^b   Katare, Om P ^b   Kaur, Inderjeet ^c   Kumar, Bhushan ^c  

^a Skin Clinic   (India)

^b PANJAB UNIVERSITY   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^d B 7 ^*  (India)

Author keywords

Adverse effects; Dithranol; Liposome; Psoriasis; Topical therapy

Indexed keywords

BASE; COAL TAR; DITHRANOL; LIPOSOME; SALICYLIC ACID;

ADULT; ARTICLE; BURNING SENSATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CLOTHING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SYNTHESIS; ERYTHEMA; FEMALE; GEL; HUMAN; INCIDENCE; LIPOGEL; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; SKIN STAINING; STAINING; STATISTICAL SIGNIFICANCE;

ADULT; ANTHRALIN; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMPOUNDING; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TREATMENT OUTCOME;

EID: 33947157611     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028729     Document Type: Article

References (20)

1. Schaefer H, Farber EM, Goldberg L, Schalla W. Limited application period for dithranol in psoriasis: Preliminary report on penetration and clinical efficacy. Br J Dermatol. 1980;102:571-3.
2. Ramsay B, Lawrence CM, Bruce JM, Schuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 1990;23:73-6.
3. Wilson JD, Ive FA. Dithrocream in psoriasis. Br J Dermatol. 1980;103:105-6.
4. Volden G, Bjomberg A, Tegner E, Pedersen NB, Arles UB, Agren S, et al. Short-contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh). 1992;172:20-2.
5. Gehring W, Ghyczy M, Gloor M, Scheer T, Roding J. Enhancement of the penetration of dithranol and increase of effect of dithranol on the skin by liposomes. Arzneimittelforschung. 1992;42:983-5.
6. Agarwal R, Katare OP, Vyas SP. Preparation and in-vitro evaluation of liposomal/niosomal delivery systems of antipsoriatic drug dithranol. Int J Pharm. 2001;228:43-52.
7. Agarwal R, Saraswat A, Kaur I, Katare OP, Kumar B. A novel liposomal formulation of dithranol in psoriasis: Preliminary results. J Dermatol. 2002;29:286-8.
8. Saraswat A, Agarwal R, Kaur I, Katare OP, Kumar B. Fabric staining properties and washability of a novel liposomal dithranol formulation. J Dermatol Treat. 2002;13:119-22.
9. Mustakallio KK. Irritation, staining and antipsoriatic activity of 10-acyl analogue of anthralin. Br J Dermatol. 1981;105(suppl 20):23-7.
10. Hiller C, Campbell C, Smeaton I. How stable is dithranol? An investigation into the degradation of different dithranol formulations. Pharm Pract. 1995;5:428-31.
11. Van Scott EJ, Yu RJ. New chemical stabilizers, vehicles and delivery systems to enhance efficacy of low strength anthralin formulations. Br J Dermatol. 1981;105(suppl 20):35-8.
12. Whitefield M. Pharmaceutical formulations of anthralin. Br J Dermatol. 1981;105(suppl 20):28-32.
13. Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev. 1996;18:335-42.
14. Lasch J, Bouwstra J. Interaction of external lipid vesicles with the skin. J Liposome Res. 1995;5:543-69.
15. Schafer-Korting M, Korting HC, Ponce-Poschl E. Liposomal tretinoin for uncomplicated acne vulgaris. Clin Investig. 1994;72:1086-91.
16. Muller K. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Biochem Pharmacol. 1997;53:1215-21.
17. Kersey P, Chapman P, Rogers S, Rawlins M, Schuster S. The inflammatory response to anthralin and its relation to aryl hydrocarbon hydroxylase. Br J Dermatol. 1981;105(suppl 20):64-7.
18. Muller K, Gawlik I. Inactivation of mouse epidermal 12-lipoxygenase by anthralin: Implications for the role of oxygen radicals. Biochem Pharmacol. 1996;51:1173-9.
19. Mustakallio KK. The history of dithranol and related hydroxyxanthrones, their efficacy, side effects and different regimens employed in the treatment of psoriasis: A review. Acta Derm Venereol Suppl (Stockh). 1992;172:7-9.
20. Kraft S, Maibach HI, Shroot B. Dithranol (Anthralin). In: Roenigk HH, Maibach HI, editors. Psoriasis. New York: Marcel Dekker, 1998. p. 435-52.